Downregulating MK5 to reduce immune escape induced by thebinding of PD-1 with PD-L1 in NSCLC
DOI:
https://doi.org/10.61173/kda2yp61Keywords:
MK5, YAP, PD-L1, immune escape, NSCLC, EGFR, targeted therapyAbstract
Lung cancer is the leading cause of cancer death in both men and women worldwide. Previous studies have indicated
that MK5 stabilizes Yes-associated Protein (YAP) in LATS1/2-null RPE1 cells, and YAP regulates PD-L1 expression in
NSCLC. Since previous studies did not associate MK5 KO with PD-L1 expression in NSCLC, this study investigates
whether downregulating MK5 in the H1299 cell line using MK5 CRISPR will reduce the expression of PD-L1 both in
vitro and in vivo conditions for NSCLC. The negative control is a scrambled CRISPR targeting vector, and the positive
control is the depletion of MK5. Through western blot and MTT in vitro and xenograft in vivo, the paper investigates
whether or not downregulating MK5 will reduce immune escape induced by the binding of PD-1 with PD-L1 in
NSCLC.
References
[1] “Lung Cancer - Non-Small Cell - Statistics.” Cancer.Net, 14 Apr. 2022, https://www.cancer.net/cancer-types/lung-cancernon-small-cell/statistics#:~:text=NSCLC%20is%20the%20 most%20common%20type%20of%20lung,people%20were%20 diagnosed%20with%20lung%20cancer%20in%202020.
[2] Hsu, Ping-Chih et al. “Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non- Small Cell Lung Cancer (NSCLC).” International journal of molecular sciences vol. 20,15 3821. 5 Aug. 2019, doi:10.3390/ ijms20153821
[3] Akbay, Esra A et al. “Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.” Cancer discovery vol. 3,12 (2013): 1355-63. doi:10.1158/2159- 8290.CD-13-0310
[4] Jimyung Seo, Min Hwan Kim, Hyowon Hong, Hyunsoo Cho, Seongyeol Park, Sang Kyum Kim, Joon Kim; MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers. Cancer Res 15 December 2019; 79 (24): 6139–6152. https://doi. org/10.1158/0008-5472.CAN-19-1339
[5] Song, Zhiwang et al. “Ruscogenin induces ferroptosis in pancreatic cancer cells.” Oncology reports vol. 43,2 (2020): 516- 524. doi:10.3892/or.2019.7425
[6] Miao, Jinbai et al. “YAP regulates PD-L1 expression in human NSCLC cells.” Oncotarget vol. 8,70 114576-114587. 9 Dec. 2017, doi:10.18632/oncotarget.23051
[7] He, Chunbo et al. “The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression.” EMBO molecular medicine vol. 7,11 (2015): 1426-49. doi:10.15252/emmm.201404976
[8] “PD-L1 Knockout A549 Cell Lysate.” Novus Biologicals, https://www.novusbio.com/products/pd-l1-lysate_nbp2 77288#:~:text=Novus%27%20KO%20cell%20lysate%20 can%20be%20used%20as,Names%20for%20PD-L1%20 Knockout%20A549%20Cell%20Lysate%20Avelumab.
[9] Yang, Chi-Hwa, et al. “EGFR over-Expression in Non-Small Cell Lung Cancers Harboring EGFR Mutations Is Associated with Marked down-Regulation of CD82.” Biochimica Et Biophysica Acta (BBA) - Molecular Basis of Disease, Elsevier, 23 Apr. 2015,https://www.sciencedirect.com/science/article/pii/ S092544391500126X.
[10] Manogaran, Prasath. (2019). Re: What kind of error in MTT assay?. Retrievedfrom:https://www.researchgate.net/post/What_ kind_of_error_in_MTT_assay/5d20705df8ea52c972719e18/ citation/download.
[11] Lin, Shian-Ren. (2019). Re: What kind of error in MTT assay?. Retrieved from:https://www.researchgate.net/post/What_ kind_of_error_in_MTT_assay/5d35423ea5a2e249bb0cc9bb/ citation/download.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
